Emv Capital (EMVC)

Sector:

Financials

 46.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 76.50p
  • 52 Week Low: 44.00p
  • Currency: UK Pounds
  • Shares Issued: 24.36m
  • Volume: 0
  • Market Cap: £11.33m
  • Beta: 0.32

NetScientific's Wanda signs orthopedics deal with HRS Home Health

By Josh White

Date: Monday 19 Mar 2018

LONDON (ShareCast) - (ShareCast News) - Healthcare intellectual property commercialisation company NetScientific announced on Monday that its portfolio company Wanda Health is expanding into orthopedics through a new partnership with HRS Home Health.
The AIM-traded firm said Wanda's predictive analytics and artificial intelligence solutions already provided remote management solutions for chronic conditions in heart and respiratory health.

It explained that the partnership with HRS, a Wanda client, brought Wanda's capabilities to the field of orthopedics, with initial pilot studies demonstrating a decrease in the length of time patients were required to remain in hospital through the use of Wanda's technology.

HRS would use Wanda telehealth and predictive analytics products to provide real-time data and informatics to orthopedic surgeons and their clinical teams.

NetScientific said HRS Home Health partnered with orthopedic surgeons in Omaha, Nebraska to collect metrics in patients' homes, which tracked patient outcomes post-surgery.

HRS reportedly identified gaps in clinical information that were not being reported to the surgeons and their clinical teams during the critical time frame from three to 14 days of post-operative care.

To improve patient outcomes, five key metrics were identified for remote telehealth data collection to assist with real time clinical oversight - knee flexion, knee extension, pain with activity, knee circumference, and quadriceps strength.

Initial pilot results demonstrated a decrease in cost per case of 18% compared to cases not involved in the pilot.

NetScientific said initial pilot cases showed a decrease in length of stay from 19.4 days to 11.5 days.

Those patients achieved desired outcomes 41% quicker than prior to the pilot.

The integration of Wanda's technology with HRS care interventions had also decreased readmissions, LOS and cost of care, NetScientific claimed.

"We are delighted to announce that Wanda is expanding its analytical focus to orthopedics, which demonstrates the flexibility and potential of the technology," said Wanda chairman and NetScientific CEO Francois Martelet.

"In particular, we are pleased that the initial pilot cases demonstrate a decrease in length of stay from 19.4 days to 11.5 days, achieving desired outcomes for patients 41% quicker when using Wanda technology."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Emv Capital Market Data

Currency UK Pounds
Share Price 46.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 76.50p
52 Week Low 44.00p
Volume 0
Shares Issued 24.36m
Market Cap £11.33m
Beta 0.32

Emv Capital Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
59.88% below the market average59.88% below the market average59.88% below the market average59.88% below the market average59.88% below the market average
67.86% below the sector average67.86% below the sector average67.86% below the sector average67.86% below the sector average67.86% below the sector average
Income Not Available
Growth Not Available

Emv Capital Dividends

No dividends found

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

Emv Capital Key Personnel

CEO Ilian Iliev
CFO Stephen Crowe

Top of Page